dAURK-4 hydrochloride

Cat. No.: HY-137344A

Molecular Formula: $C_{52}H_{53}Cl_2FN_8O_{12}$

Molecular Weight: 1071.93

Target: Aurora Kinase

Pathway: Cell Cycle/DNA Damage; Epigenetics

Storage: -20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 66.67 mg/mL (62.20 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	0.9329 mL	4.6645 mL	9.3290 mL
	5 mM	0.1866 mL	0.9329 mL	1.8658 mL
	10 mM	0.0933 mL	0.4664 mL	0.9329 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 5 mg/mL (4.66 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

dAURK-4 hydrochloride, an Alisertib derivative, is a potent and selective AURKA (Aurora A) degrader. dAURK-4 hydrochloride has anticancer effects[1].

IC_{50} & Target

Aurora A

In Vitro

dAURK-4 (125-1000 nM; 4-24 hours) hydrochloride shows degradation of AURKA in a dose-depended manner[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	MM.1S cells
Concentration:	125 nM, 250 nM, 500 nM, 1000 nM
Incubation Time:	4 hours or 24 hours

Result:	Inhibited the protein level of AURKA (Aurora A).

REFERENCES

[1]. Katherine A Donovan, et al. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. 2020 Dec 10;183(6):1714-1731.e10.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA